Posizolid

Drug Profile

Posizolid

Alternative Names: AZD 2563; AZD-5847

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Antituberculars; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gram-positive infections; Tuberculosis

Most Recent Events

  • 10 Feb 2016 Discontinued - Phase-I for Tuberculosis in USA (PO) prior to February 2016
  • 10 Feb 2016 Discontinued - Phase-II for Tuberculosis (Treatment-naive) in South Africa (PO) prior to February 2016 (AstraZeneca's pipeline, February 2016)
  • 13 Oct 2015 No development reported - Phase-I for Tuberculosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top